Table 5. HIF1A polymorphisms and clinicopathological characteristics in patients with PCa.
| Group | rs11549465, n (%) | Adjusted OR (95%CI)b | rs11549467, n (%) | Adjusted OR (95%CI)b | rs2057482, n (%) | Adjusted OR (95%CI)b | |||
|---|---|---|---|---|---|---|---|---|---|
| CC | CT+TT | GG | GA+AA | CC | CT+TT | ||||
| Clinical stagea | |||||||||
| Localized | 492 (93.0) | 37 (7.0) | 1.00 (reference) | 491 (92.8) | 38 (7.2) | 1.00 (reference) | 338 (63.9) | 191 (36.1) | 1.00 (reference) |
| Advanced | 120 (90.2) | 13 (9.8) | 1.43 (0.73–2.78) | 123 (92.5) | 10 (7.5) | 1.06 (0.51–2.20) | 80 (60.2) | 53 (39.9) | 1.16 (0.78–1.71) |
| Gleason score | |||||||||
| <7 | 212 (92.2) | 18 (7.8) | 1.00 (reference) | 218 (94.8) | 12 (5.2) | 1.00 (reference) | 136 (59.1) | 94 (48.9) | 1.00 (reference) |
| =7 | 198 (90.4) | 21 (9.6) | 1.28 (0.77–2.15) | 203 (92.7) | 16 (7.3) | 1.60 (0.88–2.92) | 141 (64.4) | 78 (35.6) | 0.83 (0.61–1.13) |
| >7 | 202 (94.8) | 11 (5.2) | 0.64 (0.33–1.23) | 193 (90.6) | 20 (9.4) | 2.14 (1.22–3.75)c | 141 (66.2) | 72 (33.8) | 0.76 (0.55–1.04) |
| PSA (ng ml−1) | |||||||||
| ≤20 | 271 (92.2) | 23 (7.8) | 1.00 (reference) | 277 (94.2) | 17 (5.8) | 1.00 (reference) | 178 (60.5) | 116 (39.5) | 1.00 (reference) |
| >20 | 341 (92.7) | 27 (7.3) | 0.94 (0.53–1.68) | 337 (91.6) | 31 (8.4) | 1.49 (0.81–2.76) | 240 (65.2) | 128 (34.8) | 0.82 (0.60–1.13) |
Abbreviations: CI, confidence interval; OR, odds ratio; PCa, prostate cancer; PSA, prostate-specific antigen.
a
Localized: T1–2N0M0; advanced: T3–4NxMx or TxN1Mx or TxNxM1. Clinical staging according to the international tumor-node metastasis system for PCa.
b
Adjusted for age, smoking, drinking status and family history of cancer in logistic regression model.
c
Bold-faced values indicate significant difference at the 5% level (P=0.032).